Department of Cardiology & Vascular Medicine, Dr Soetomo General Hospital.
Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
J Pak Med Assoc. 2024 Jun;74(6 (Supple-6)):S28-S33. doi: 10.47391/JPMA.S6-ACSA-06.
To examine the impact of trimetazidine on skeletal muscle function in patients suffering from peripheral artery disease.
The systematic review was conducted from July 20 to November 22, 2022, in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis and comprised search for interventional studies on MEDLINE, ProQuest, Scopus and ScienceDirect databases using key words "peripheral artery disease" and "trimetazidine" or their synonyms. The cut-off date for the search was July 21, 2022. Clinical parameters, including Ankle-Brachial Index, Maximum Walking Distance, Maximum Walking Time and Pain Onset Time, were analysed both narratively and quantitatively whenever possible.
Of the 587 studies initially identified, 12(2%) were shortlisted. Of them, 2(16.7%) qualified for detailed analysis, comprising 172 patients with intermittent claudication. There was no significant difference between the examined groups' Ankle-Brachial Index values at baseline and post-intervention (p=0.83). Maximum Walking Distance improvement was significantly higher (p=0.0006) in trimetazidine group compared to control group. Maximum Walking Time MWT and Pain Onset Time were significantly different between control and trimetazidine groups (p<0.05).
Trimetazidine's anti-ischaemic effect in peripheral artery disease patients improved Maximum Walking Distance, while it had no significant influence on Ankle-Brachial Index. Well-designed studies addressing the issue are needed.
研究曲美他嗪对患有外周动脉疾病患者骨骼肌功能的影响。
系统评价于 2022 年 7 月 20 日至 11 月 22 日进行，遵循系统评价和荟萃分析的首选报告项目，并使用关键词“外周动脉疾病”和“曲美他嗪”或其同义词在 MEDLINE、ProQuest、Scopus 和 ScienceDirect 数据库中进行干预性研究检索。搜索截止日期为 2022 年 7 月 21 日。临床参数，包括踝肱指数、最大步行距离、最大步行时间和疼痛发作时间，在可能的情况下进行叙述性和定量分析。
最初确定的 587 项研究中，有 12 项（2%）被列入候选名单。其中，有 2 项（16.7%）符合详细分析的标准，包括 172 例间歇性跛行患者。检查组的踝肱指数值在基线和干预后没有显著差异（p=0.83）。与对照组相比，曲美他嗪组的最大步行距离改善明显更高（p=0.0006）。最大步行时间和疼痛发作时间在对照组和曲美他嗪组之间有显著差异（p<0.05）。
曲美他嗪在外周动脉疾病患者中的抗缺血作用改善了最大步行距离，而对踝肱指数没有显著影响。需要进行设计良好的研究来解决这个问题。
